Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04751864 · ClinicalTrials.gov registry record · Phase 4
Brain Stimulation & Generalized Anxiety Study
A Phase 4 study of Anxiety and Generalized Anxiety Disorder, sponsored by ProofPilot.
- Active
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT04751864 is a Phase 4 study of Anxiety and Generalized Anxiety Disorder that is active but no longer recruiting, run by ProofPilot. The registered enrollment target is 150 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04751864, a Phase 4 study of Anxiety and Generalized Anxiety Disorder, is active but no longer recruiting, sponsored by ProofPilot.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device on Generalized Anxiety Disorder using two (2) 20-minute per day treatment sessions over eight weeks.
Conditions Studied
Interventions
- DEVICE Cranial Electrotherapy Stimulator (CES) Device
Study Locations (1)
New York
- ProofPilot (Remote Virtual Trial) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2021-06-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04751864
The ClinicalTrials.gov registry entry for NCT04751864 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (66% lower). The listed sponsor is ProofPilot, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Anxiety appearing as the primary indexed condition, and to 1 intervention - of which Cranial Electrotherapy Stimulator (CES) Device is the first listed.
NCT04751864 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04751864 about?
NCT04751864 is a clinical study titled "Brain Stimulation & Generalized Anxiety Study". Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device on Generalized Anxiety Disorder using two (2) 20-minute per day treatment sessions over eight weeks.
What is the current status of trial NCT04751864?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2020-10-15. Estimated completion is 2021-06-21.
What conditions does trial NCT04751864 study?
This clinical trial studies the following conditions: Anxiety, Generalized Anxiety Disorder, Generalized Anxiety.
What interventions are being tested in trial NCT04751864?
The interventions under investigation include: Cranial Electrotherapy Stimulator (CES) Device (DEVICE).
Who is sponsoring clinical trial NCT04751864?
This trial is sponsored by ProofPilot, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04751864 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
-
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
RECRUITING · Phase 4
-
IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED
RECRUITING · Phase 4
-
Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting
COMPLETED · Phase 4
-
Epidiolex® for Anxiety in Pediatric Epilepsy
COMPLETED · Phase 4
-
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.